Netherlands - Re-Imbursed Pharmaceutical Market

Since 2014, Netherlands Re-Imbursed Pharmaceutical Market was up 3.6points year on year. At 19.7 Percent of Generics in Value in 2019, the country was number 13 comparing other countries in Re-Imbursed Pharmaceutical Market. Netherlands is overtaken by Switzerland, which was number 12 with 20.4 Percent of Generics in Value and is followed by Ireland at 15.5 Percent of Generics in Value. Austria ranked the highest with 52.2 Percent of Generics in Value in 2019, a growth of 2.8points compared to 2018. United Kingdom, Turkey and New Zealand respectively ranked number 2, 3 and 4 in this ranking. Denmark recorded the best 5 years average growth at +6.9points per year, while Slovakia recorded the worst performance at -7.8points per year.

Loading...

Date Percent of Generics in Value
2019 19.70
2018 20.00
2017 17.90
2016 16.80
2015 16.50
Download all data from 2000 to 2019

How does Netherlands rank in Re-Imbursed Pharmaceutical Market?

# 17 Countries Percent of Generics in Value Last YoY 5‑years CAGR
1 #1
Austria
52.20 % 2019 +2.8 % +2.2 % View data
2 #2
United Kingdom
38.50 % 2019 +2.1 % +2.6 % View data
12 #12
Switzerland
20.40 % 2019 +1.5 % +1.5 % View data
13 #13
Netherlands
19.70 % 2019 -1.5 % +3.6 % View data
14 #14
Ireland
15.50 % 2019 +4.0 % -1.1 % View data
Compare all 17 countries

Go Top